Tavira Therapeutics

Belgium
Teuven, Limburg, Belgium, 3001

Company profile

Tavira Therapeutics company profile

Tavira Therapeutics develops an advanced platform that enhances gene delivery of AAV (adeno-associated virus). The company's approach is to equip AAV vectors with specific molecules that allow for more targeted and safer gene therapies, representing a significant advancement in the field. Founded as a spin-off from KU Leuven and Trellis, Tavira is leveraging groundbreaking research to develop modular AAV capsid technologies to improve gene therapy treatments.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2023-01-01, Year

Headquarters

Postal code
3001
Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
2
Total equity funding
$1.1M
Last funding
Grant / $356,791 / 2025-02-04
Last equity funding
Pre Seed / $1.1M
Investors
3
Lead investors
1
Founders
4

Founders and investors

Founders

Benjamien MoeyaertEls HenckaertsInge Van HoveVibha Tamboli

Lead investors

Flanders Innovation & Entrepreneurship (VLAIO)

Investors

Flanders Innovation & Entrepreneurship (VLAIO)Gemma Frisius FundGeneral Inception